Inhibikase Therapeutics IKT
NASDAQ IKT
$1.60 +0.05 (+3.23%)
As of: Nov 11, 2026 · 11:52 AM EST

Inhibikase Therapeutics (IKT) Shares Outstanding (Diluted) (2021 - 2026)

Updated

Inhibikase Therapeutics' Shares Outstanding (Diluted) was 174.57 million in Q2 2026, up 93.9% from 90.01 million a year earlier and up 1.3% from the prior quarter.

Analysis

Inhibikase Therapeutics (IKT) Shares Outstanding (Diluted) (2021 - 2026) Analysis & Trends

For FY2025, Shares Outstanding (Diluted) at Inhibikase Therapeutics came in at 98.31 million, up 314.6% from FY2024.

  • Shares Outstanding (Diluted) has now increased for four consecutive years, with a four-year compound annual growth rate of 138.6% (FY2021 to FY2025).
  • In earlier years, Shares Outstanding (Diluted) was 23.71 million in FY2024 (+344.6%), 5.33 million in FY2023 (+26.9%), 4.2 million in FY2022 (+38.5%) and 3.03 million in FY2021.
  • The Q2 2026 figure marks the highest quarterly Shares Outstanding (Diluted) in data going back to Q2 2021.
  • Compared with a year earlier, Shares Outstanding (Diluted) has increased for four straight quarters, with growth averaging 304.3% over the last six quarters.
  • The year-over-year growth in Shares Outstanding (Diluted) has ranged between 0.3% (Q3 2022) and 913.8% (Q3 2025) over the last five years.
  • Per Business Quant data, IKT's Shares Outstanding (Diluted) in the three quarters before Q2 2026 was 172.31 million (Q1 2026), 98.31 million (Q4 2025) and 90.05 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Shares Outstanding (Dil.) (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 893.40 Mn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 2.45 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 1.77 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 2.48 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn - 1.96 Bn
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 1.56 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 546.00 Mn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 1.25 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 5.75 Bn
10 Inhibikase Therapeutics 281.11 Mn -420.36 Mn - 196.94 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 196.94 Mn
Jun 30, 2026 174.57 Mn
Mar 31, 2026 172.31 Mn
Dec 31, 2025 98.31 Mn
Sep 30, 2025 90.05 Mn
Jun 30, 2025 90.01 Mn
Mar 31, 2025 89.54 Mn
Dec 31, 2024 23.71 Mn
Sep 30, 2024 8.88 Mn
Jun 30, 2024 7.54 Mn
Mar 31, 2024 6.34 Mn
Dec 31, 2023 5.33 Mn
Sep 30, 2023 5.34 Mn
Jun 30, 2023 5.23 Mn
Mar 31, 2023 4.59 Mn
Dec 31, 2022 4.20 Mn
Sep 30, 2022 4.20 Mn
Jun 30, 2022 4.20 Mn
Mar 31, 2022 4.20 Mn
Dec 31, 2021 3.03 Mn
API Access

Inhibikase Therapeutics Shares Outstanding (Diluted) API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=shares-outstanding-diluted&ticker=IKT&period=max&api_key=YOUR_API_KEY